Peripheral and Intestinal T-regulatory Cells are Upregulated in Children with Inflammatory Bowel Disease at Onset of Disease

References

• Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. (2001). CD4+CD25high regulatory cells in human peripheral blood. J Immunol, 167, 1245–1253.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Christie J, Ramsdell F, et al. (2001). The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet, 27, 20–21.
   PubMed Web of Science ®Google Scholar
• Bonelli M, Savitskaya A, Steiner CW, et al. (2009). Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunol, 182, 1689–1695.
   PubMed Web of Science ®Google Scholar
• Boschetti G, Nancey S, Sardi F, et al. (2011). Therapy with anti-TNFalpha antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. Inflamm Bowel Dis, 17, 160–170.
   PubMed Web of Science ®Google Scholar
• Brunkow ME, Jeffery EW, Hjerrild KA, et al. (2001). Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet, 27, 68–73.
   PubMed Web of Science ®Google Scholar
• Costantino CM, Baecher-Allan C, Hafler DA. (2008). Multiple sclerosis and regulatory T cells. J Clin Immunol, 28, 697–706.
   PubMed Web of Science ®Google Scholar
• Curotto de Lafaille MA, Lafaille JJ. (2009). Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity, 30, 626–635.
   PubMed Web of Science ®Google Scholar
• Dal Ben ER, do Prado CH, Baptista TS, et al. (2014). Patients with systemic lupus erythematosus and secondary antiphospholipid syndrome have decreased numbers of circulating CD4(+)CD25(+)Foxp3(+) Treg and CD3(-)CD19(+) B cells. Rev Bras Reumatol, 54, 241–246.
   Google Scholar
• Daperno M, D’Haens G, Van Assche G, et al. (2004). Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: SES-CD. Gastrointest Endosc, 60, 505–512.
   PubMed Web of Science ®Google Scholar
• Dieckmann D, Plottner H, Berchtold S, et al. (2001). Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med, 193, 1303–1310.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Biancheri P, Piconese S, et al. (2010). Peripheral regulatory T cells and serum transforming growth factor-beta: relationship with clinical response to infliximab in Crohn’s disease. Inflamm Bowel Dis, 16, 1891–1897.
   PubMed Web of Science ®Google Scholar
• Geboes K, Dalle I. (2002). Influence of treatment on morphologic features of mucosal inflammationn. Gut, 50(Suppl), 47–52.
   Google Scholar
• Geboes K, Riddell R, Ӧst A, et al. (2000). A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut, 47, 404–409.
   PubMed Web of Science ®Google Scholar
• Gerli R, Nocentini G, Alunno A, et al. (2009). Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun Rev, 8, 426–430.
   PubMed Web of Science ®Google Scholar
• Guidi L, Felice C, Procoli A, et al. (2013). FOXP3(+) T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFalpha agents. Biomed Res Int, 286368, 26.
   Google Scholar
• Han GM, O’Neil-Andersen NJ, Zurier RB, Lawrence DA. (2008). CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell Immunol, 253, 92–101.
   PubMed Web of Science ®Google Scholar
• Holmen N, Lundgren A, Lundin S, et al. (2006). Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis, 12, 447–456.
   PubMed Web of Science ®Google Scholar
• Holtta V, Sipponen T, Westerholm-Ormio M, et al. (2012). In Crohn’s Disease, Anti-TNF-alpha Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells. ISRN Gastroenterol, 505432, 14.
   Google Scholar
• Hori S, Nomura T, Sakaguchi S. (2003). Control of regulatory T cell development by the transcription factor Foxp3. Science, 299, 1057–1061.
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Saubermann LJ, Smith L, et al. (2007). Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut, 56, 1696–1705.
   PubMed Web of Science ®Google Scholar
• Li Z, Arijs I, De Hertogh G, et al. (2010). Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis, 16, 1299–1310.
   PubMed Web of Science ®Google Scholar
• Lin SC, Chen KH, Lin CH, et al. (2007). The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest, 37, 987–996.
   PubMed Web of Science ®Google Scholar
• Makita S, Kanai T, Oshima S, et al. (2004). CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol, 173, 3119–3130.
   PubMed Web of Science ®Google Scholar
• Maul J, Loddenkemper C, Mundt P, et al. (2005). Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology, 128, 1868–1878.
   PubMed Web of Science ®Google Scholar
• Otley AR, Loonen H, Parekh N, et al. (1999). Assessing activity of pediatric Crohn’s disease. Which index to use? Gastroenterology 116, 527–531.
   PubMed Web of Science ®Google Scholar
• Podolsky DK. (2002). Inflammatory bowel disease. N Engl J Med, 347, 417–429.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, Ono M. 2008. Regulatory T cells and immune tolerance. Cell, 133, 775–787.
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. (1987). Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med, 317, 1625–1629.
   PubMed Web of Science ®Google Scholar
• Scotto L, Naiyer AJ, Galluzzo S. (2004). Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28- T suppressor cells. Hum Immunol, 65, 1297–1306.
   PubMed Web of Science ®Google Scholar
• Sloan S, Maxwell P, Salto-Tellez M, Loughrey MB. (2014). FOXP3+ regulatory T-cell counts correlate with histological response in Crohn’s colitis treated with infliximab. Pathol Int, 64, 624–627.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Jagger AL, Konya C, et al. (2012). CD8+CD45RA+CCR7+FOXP3+ T cells with immunosuppressive properties: a novel subset of inducible human regulatory T cells. J Immunol, 189, 2118–2130.
   PubMed Web of Science ®Google Scholar
• Turner D, Otley AR, Mack D, et al. (2007). Development, validation and evaluation of pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 133, 423–432.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu XP, Zhao ZB, et al. (2011). Expression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease. J Dig Dis, 12, 286–294.
   PubMed Web of Science ®Google Scholar